Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Marroquin Belaunzaran, Osiris ^a   Cordero, Maria Isabel ^a   Setola, Veronica ^a   Bianchi, Siro ^b   Galli, Carmela ^b   Bouche, Nicolas ^a   Mlynarik, Vladimir ^a   Gruetter, Rolf ^a   Sandi, Carmen ^a   Bensadoun, Jean Charles ^a   Molinari, Maurizio ^b   Aebischer, Patrick ^a  

^a EPFL   (Switzerland)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; DNA; POLYMER; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ALLOTRANSPLANTATION; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR DISORDER; BIOENGINEERING; CELL ENCAPSULATION; CELL ISOLATION; CELL TRANSPLANTATION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DNA MODIFICATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TARGETING; FEMALE; FUNCTIONAL ASSESSMENT; IN VITRO STUDY; MEMORY; MOUSE; MYOBLAST; NONHUMAN; PASSIVE IMMUNIZATION; PEPTIDE SYNTHESIS; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN SYNTHESIS INHIBITION;

ANIMALS; CELL LINE; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN FRAGMENTS; MICE;

MUS MUSCULUS;

EID: 80052151341     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018268     Document Type: Article

References (37)

1. Deyev SM, Lebedenko EN, (2008) Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. Bioessays 30: 904-918.
2. Nieri P, Donadio E, Rossi S, Adinolfi B, Podesta A, (2009) Antibodies for therapeutic uses and the evolution of biotechniques. Curr Med Chem 16: 753-779.
3. Nelson AL, Reichert JM, (2009) Development trends for therapeutic antibody fragments. Nat Biotechnol 27: 331-337.
4. Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, et al. (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75: 1472-1474.
5. Foster JK, Verdile G, Bates KA, Martins RN, (2009) Immunization in Alzheimer's disease: naive hope or realistic clinical potential? Mol Psychiatry 14: 239-251.
6. Geylis V, Steinitz M, (2006) Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Autoimmun Rev 5: 33-39.
7. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, et al. (2008) 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging.
8. Wilcock DM, Colton CA, (2008) Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 15: 555-569.
9. Lichtlen P, Mohajeri MH, (2008) Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem 104: 859-874.
10. Chames P, Van Regenmortel M, Weiss E, Baty D, (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157: 220-233.
11. Paganetti P, Calanca V, Galli C, Stefani M, Molinari M, (2005) beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. J Cell Biol 168: 863-868.
12. Glenner GG, Wong CW, (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890.
13. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, et al. (2002) Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298: 1379.
14. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, et al. (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76: 173-181.
15. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, et al. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94: 13287-13292.
16. Steele RJ, Morris RG, (1999) Delay-dependent impairment of a matching-to-place task with chronic and intrahippocampal infusion of the NMDA-antagonist D-AP5. Hippocampus 9: 118-136.
17. Kubetzko S, Balic E, Waibel R, Zangemeister-Wittke U, Pluckthun A, (2006) PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J Biol Chem 281: 35186-35201.
18. Furrer E, Hulmann V, Urech DM, (2009) Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain. J Neuroimmunol 215: 65-72.
19. Fukuchi K, Tahara K, Kim HD, Maxwell JA, Lewis TL, et al. (2006) Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis 23: 502-511.
20. Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, et al. (2006) Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci 26: 11923-11928.
21. Wang YJ, Pollard A, Zhong JH, Dong XY, Wu XB, et al. (2009) Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease. Neurobiol Aging 30: 364-376.
22. Holliger P, Hudson PJ, (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136.
23. Le Cudennec C, Faure A, Ly M, Delatour B, (2008) One-year longitudinal evaluation of sensorimotor functions in APP751SL transgenic mice. Genes Brain Behav 7 (Suppl 1): 83-91.
24. Lee KW, Lee SH, Kim H, Song JS, Yang SD, et al. (2004) Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein. J Neurosci Res 76: 572-580.
25. Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, et al. (1999) Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A 96: 14088-14093.
26. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, et al. (2003) Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 17: 388-396.
27. Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, et al. (2001) Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 21: 1619-1627.
28. Aebischer P, Schluep M, Deglon N, Joseph JM, Hirt L, et al. (1996) Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 2: 696-699.
29. Aebischer P, Ridet J, (2001) Recombinant proteins for neurodegenerative diseases: the delivery issue. Trends Neurosci 24: 533-540.
30. Sajadi A, Bensadoun JC, Schneider BL, Lo Bianco C, Aebischer P, (2006) Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease. Neurobiol Dis 22: 119-129.
31. Schneider BL, Schwenter F, Pralong WF, Aebischer P, (2003) Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery. Mol Ther 7: 506-514.
32. Kishima H, Poyot T, Bloch J, Dauguet J, Conde F, et al. (2004) Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiol Dis 16: 428-439.
33. Bloch J, Bachoud-Levi AC, Deglon N, Lefaucheur JP, Winkel L, et al. (2004) Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 15: 968-975.
34. Paxinos G, Franklin KBJ, (2001) The mouse brain in stereotaxic coordinates San Diego, CA Academic pp. xxv, [264].
35. Wilcock DM, Gordon MN, Morgan D, (2006) Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc 1: 1591-1595.
36. Carty NC, Nash K, Lee D, Mercer M, Gottschall PE, et al. (2008) Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP+PS1 transgenic mice. Mol Ther 16: 1580-1586.
37. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842.